Allergan working with FDA on possible safety concerns over IBS drug & more—3 GI companies making waves

Here are three updates on GI companies to note:

After reporting non-statistically significant results in a phase-II study, Cambridge, Mass.-based Seres Therapeutics is launching a revised phase-II study for its SER-109 Clostridium Difficile treatment.

A Spherix Global Insights report found Janssen Pharmaceuticals' Stelara, an alternative mechanism biologic, was the most exciting advancement to happen to inflammatory bowel disease in 2016.

The FDA issued a communication claiming Viberzi — a medicine used for patients with irritable bowel syndrome with diarrhea — could increase pancreatitis risk in patients without gallbladders. Parsippany-Troy Hills, N.J.-based Allergan manufactures the drug. The FDA and Allergan are addressing potential safety concerns.

More articles on gastroenterology:
GI leader to know: Dr. John Inadmoi of University of Washington Medicine
Series Therapeutics initiating new phase-II study for C. Diff treatment: 6 insights
National Cancer Institute's colorectal cancer screening initiative seeks to increase Kentucky screening rates: 4 points

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers